Research programme: ammonium tetrathiomolybdate injection - Magnus Life Science

Drug Profile

Research programme: ammonium tetrathiomolybdate injection - Magnus Life Science

Alternative Names: Injectable therapy - Magnus Oxygen; Reperfusion injury therapeutic - Magnus Oxygen; TTM injection - Magnus Oxygen

Latest Information Update: 06 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Magnus Life Science; University College London
  • Class Heavy metals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic heart failure; Myocardial infarction
  • Research Reperfusion injury; Stroke

Most Recent Events

  • 21 Jan 2015 Early research in Stroke in United Kingdom (Injection)
  • 21 Jan 2015 Preclinical trials in Chronic heart failure (Prevention) in United Kingdom (Injection)
  • 21 Jan 2015 Preclinical trials in Myocardial infarction (STEMI, Prevention) in United Kingdom (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top